- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06642129
A Prospective Observational Study of Perioperative Lumbar Puncture Pressure and Shunt Valve Pressure Management in Patients with Communicating Hydrocephalus Undergoing Lumboperitoneal Shunt Surgery (LPP-LPS)
October 11, 2024 updated by: Junfeng Feng, RenJi Hospital
A Prospective Observational Study of Perioperative Lumbar Puncture Pressure and Shunt Valve Pressure Management in Patients with Traffic Hydrocephalus Undergoing Lumbopeitoneal Shunt Surgery
Target population: patients 18 years of age or older who require surgical treatment with lumboperitoneal shunt surgery for traffic hydrocephalus Estimated sample size: 30 cases.
Study design: this study is a multicenter prospective observational study, with lumbar puncture pressure measurement before and during surgery, and shunt valve setting pressure set according to the requirements of clinical practice in the hospital where it is performed, and the collection of relevant data, including preoperative lumbar puncture pressure, intraoperative lumbar puncture pressure after anesthesia, shunt valve initial pressure, shunt valve pressure at 6 months pressure, length of the intravertebral shunt, and length of the intraperitoneal shunt.
Complications, shunt effects, and the number of shunt valve adjustments during the 6-month period were also observed and recorded.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Junfeng Feng Chief Director, MD,PhD
- Phone Number: 86-13512193229
- Email: fengjfmail@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Department of Neurosurgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
-
Contact:
- Junfeng Feng, MD, PhD
- Phone Number: 86-21-68383707
- Email: fengjfmail@163.com
-
Contact:
- Yanqing Ni, MD
- Phone Number: 86-21-68383707
- Email: pd120xz@126.com
-
Contact:
- Qing Mao, MD, PhD
-
Contact:
- Junfeng Feng, MD, PhD
-
Contact:
- Ru Gong, MD
-
Contact:
- Jiyuan Hui, MD
-
Contact:
- Ke Cao, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients 18 years of age and older who require surgical treatment with lumboperitoneal shunt for communicating hydrocephalus
Description
Inclusion Criteria:
- Age of 18 years or older;
- Confirmed diagnosis of communicating hydrocephalus;
- Signed informed consent for surgery and informed consent for research.
Exclusion Criteria:
- Pregnant women;
- Inappropriate for lumboperitoneal shunt surgery despite the diagnosis of communicating hydrocephalus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Oberservation Group
Patient requiring surgical treatment with lumboperitoneal shunt for communicating hydrocephalus
|
Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
primary outcome
Time Frame: preoperation to 6 months after surgery
|
|
preoperation to 6 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
secondary outcome
Time Frame: preoperation to 6 months after surgery
|
The numbers of complications related to the lumboperitoneal shunt at 6 months after the shunt operation, including: subdural hemorrhage, ventricular hemorrhage, intracerebral hemorrhage, subdural effusion, shunt obstruction, resetting the shunt, intracranial infection, and epilepsy.
|
preoperation to 6 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
September 15, 2024
First Submitted That Met QC Criteria
October 11, 2024
First Posted (Actual)
October 15, 2024
Study Record Updates
Last Update Posted (Actual)
October 15, 2024
Last Update Submitted That Met QC Criteria
October 11, 2024
Last Verified
September 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LY2024-070-B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hydrocephalus, Communicating
-
Duke UniversityPediatric Hydrocephalus Foundation; Children's Miracle Network HospitalsCompletedCommunicating HydrocephalusUnited States
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...Active, not recruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLCTerminatedPilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating HydrocephalusHydrocephalus | Hydrocephalus, CommunicatingUnited States
-
Beijing Tiantan HospitalRecruitingCommunicating Hydrocephalus | Cerebral Intraventricular Hemorrhage | Secondary Normal Pressure Hydrocephalus | Post Hemorrhagic HydrocephalusChina
-
University of ZurichSuspendedShunt; Complications, Ventricular (Communicating)Switzerland
-
University of Kansas Medical CenterWithdrawnLow Pressure Hydrocephalus
-
Göteborg UniversityDepartment of Neurological Surgery, Sahlgrenska University Hospital; Hydrocephalus... and other collaboratorsNot yet recruitingNormal Pressure Hydrocephalus | Normal Pressure Hydrocephalus Patients
-
Umeå UniversityCompletedIdiopathic Normal Pressure Hydrocephalus
-
Mayo ClinicTerminatedNormal Pressure Hydrocephalus PatientsUnited States
-
Umeå UniversityCompleted
Clinical Trials on surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
-
Guo ShiWeiCompletedNeoadjuvant Therapy | Pancreatic Ductal Adenocarcinoma (PDAC) | Circulating Tumor Cells (CTCs)China
-
Çanakkale Onsekiz Mart UniversityCanakkale 18 Mart University Health Research and Application HospitalActive, not recruitingDegeneration Disc Intervertebral | miRNATurkey
-
Haydarpasa Numune Training and Research HospitalCompleted
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
King's College Hospital NHS TrustMedtronicNot yet recruitingGBM | Brain TumoursUnited Kingdom
-
Fondazione Ricerca TraslazionaleRecruiting
-
Nanfang Hospital, Southern Medical UniversityActive, not recruitingEsophageal Cancer (EsC)China
-
Sebahattin Celik MDActive, not recruiting
-
University Hospital, BonnRecruitingLung Cancer Non-Small Cell Cancer (NSCLC)Germany
-
University Hospital, GrenobleEtablissement Français du SangNot yet recruitingEndometriosis | Immunity | MicrobiotaFrance